PFA Outcome of the Board Meeting and Submission of Audited Financial Results for the quarter and financial year ended 31st March, 2026 as required u/r 33 of the SEBI (LODR) Regulations, 2015
Awaiting price reaction for this filing.
MPS Pharmaa Limited reported a net loss of Rs. 101.22 lakh for FY 2026, compared to a loss of Rs. 88.81 lakh in FY 2025. Total income declined to Rs. 3.56 lakh from Rs. 4.77 lakh. The company has recorded a qualified opinion from auditors due to two issues: Rs. 53.80 lakh investment in unquoted equity shares cannot be physically verified and fair value was not determined per Ind AS, and Rs. 2.41 crore capital work-in-progress has been stalled requiring impairment evaluation. These audit qualifications are repetitive since 2017-18. The auditor emphasized that the company has no income from business operations for a long period. BSE has suspended trading due to unpaid listing fees since FY 2021-22, with trading now restricted to T-for-T on the first trading day weekly. Reserves stand negative at Rs. 1,904.29 lakh.
The stock is a high-risk investment with suspended trading, persistent losses, negative reserves, and repetitive qualified audit opinions since 2017-18. The going concern assumption is under stress given zero operating income and stalled projects.